165 results about "Cell marker" patented technology

The present invention inter alia pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor-associated carbohydrate antigen as marker for cancer stem cells.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.

The invention provides a positioning method and a positioning device. The positioning device applied to a base station side comprises the following steps: acquiring the positioning measurement information of a terminal; receiving a positioning measurement request triggered by a preset positioning entity, wherein the positioning measurement request contains an indication for positioning and measuring the terminal by virtue of a coverage enhancement grade; and sending positioning measurement information of the terminal to the preset positioning entity according to the positioning measurement request so as to drive the preset positioning entity to position the terminal according to the positioning measurement information. According to the embodiment of the invention, the terminal is roughly positioned by a network side through the coverage enhancement grade and a service cell marker of the terminal, so that the extra expenditure of the terminal caused by the positioning of the terminal in the coverage enhancement grade range is avoided, the complexity of the terminal is reduced, and the power consumption of the terminal is saved; or the terminal is subjected to positioning measurement by the network side through a repeated sending property of the coverage enhancement grade, so that a relatively accurate positioning measurement result is obtained, and the positioning measurement precision is improved.

The present invention provides polynucleotides and polypeptides (VECSM polynucleotides and polypeptides) that are differentially expressed in vascular endothelial cells. The invention further provides a variety of compositions, diagnostic, and therapeutic methods based on identification of these markers. In particular, the invention provides a targeting agent linked to a functional moiety, wherein the functional moiety can comprise any of a number of different agents, including imaging agents, cytotoxic agents, and stimulators or inhibitors of angiogenesis.

An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same. The present inventors discovered that highly pure colon cancer stem cells (CSC) can be obtained in a large quantity, and identified two types of states of colon CSCs distinguishable through Lgr5 expression.

The invention discloses a sub-totipotent stem cell from cut human umbilical cord or placenta, wherein the cell marker is CD151<+>OCT4<+>CD184<->; the cell grows adhering to the wall in a culture container and can differentiate to the body entoderm, mesoblast and ectoderm tissues. The invention also discloses a preparation method of the sub-totipotent stem cell and an application thereof for preparing drug for treating cell injuries or cell aging diseases, and an application thereof as a carrier cell of a gene treatment drug.

The invention relates to a method and apparatus for updating a notification area, and belongs to the technical field of wireless communication. The method includes the following steps: in a non-active state, based on a stored cell marker list, determining a first cell marker for currently updating a notification area, wherein the cell marker list stores a plurality of cell markers and the current signal intensity of the cell corresponding to each cell; transmitting a first notification region updating request to a base station, wherein the first notification region updating request carries a first cell marker and a base station marker of the base station which is connected to when the notification region updating is conducted previously; and receiving an allowance updating notice transmitted by the base station, updating the notification region as the cell corresponding to the first cell marker. According to the invention, when the UE is in a non-active state, the notification region is updated as the cell corresponding to the first cell marker, and the method herein can update the notification region if the notification region changes.

The invention discloses new application of axitinib. Axitinib can be used for preparing medicine for promoting white fat cell browning and used for preventing and treating obesity and diseases related to obesity. The medicine can promote primary white fat cell browning in vitro, thereby enhancing expression of brown fat cell marker gene uncoupling protein 1 (UCP1), and can promote the increase of beige fat cells in white fat tissue of groin and the increase of expression of UCP1; the medicine can resist obesity and insulin insensitivity caused by high-fat diet and has an effect on treating fatty livers.

The present invention discloses a method for simultaneous detection of cancer-associated fibroblasts and expressed proteins thereof, belonging to the technical field of tissue immunofluorescence. According to the method, a first type of quantum dot is used for labeling the antibody of a cell marker of the cancer-associated fibroblasts, or labeling a secondary antibody capable of specific binding to the antibody of the cell marker of the cancer-associated fibroblasts, or labeling streptavidin, and at least a second type of quantum dot is used for labeling the antibody of an expressed protein of the cancer-associated fibroblasts, or labeling a secondary antibody capable of specific binding to the antibody of the expressed protein of the cancer-associated fibroblasts, or labelling streptavidin; wherein the emission wavelengths of the first type of quantum dot and the second type of quantum dot are different from each other, and the first type of quantum dot and the second type of quantum dot does not label the streptavidin simultaneously. The invention also discloses a kit for simultaneous detection of cancer-associated fibroblasts and expressed protein thereof. The method of the invention is simple, efficient, accurate, and simultaneous in detection, suitable for promotion to the simultaneous labeling and quantitative analysis of a variety of other cancer-associated markers.

Disclosed is an isolated bone marrow stem cell (BMSC) having undetectable or low levels of selected cell markers including those typical of endothelial, neuronal and smooth muscle cells. Also disclosed are grafts and pharmaceutical products that include such cells. Methods of making the BMSCs are also provided. The invention has a wide spectrum of useful applications including use in the prevention and treatment of cardiovascular disease.

The invention provides endothelial cell markers and kit for predicting a cancer immunotherapy effect. The endothelial cell markers are VWF, HYAC2, FAM124B, ROBO4, ARHGEF15, ACVRL1, TIE1 and MMRN2. Thekit comprises at least specific primers for VWF, HYAC2, FAM124B, ROBO4, ARHGEF15, ACVRL1, TIE1 or MMRN2 genes. The kit includes at least a specific primer for the VWF, HYAC2, FAM124B, ROBO4, ARHGEF15, ACVRL1, TIE1 or MMRN2 genes. In the technical scheme of the invention, compared with a traditional PD-L1 expression amount based biomarker for predicting a cancer immune checkpoint blocking treatment effect is higher in accuracy, and the curative effect of a cancer patient using the immune checkpoint blocking treatment can be better predicted. In addition, only a basic RT-qPCR technology is needed for detection, the operation is relatively simple, the cost is low, the endothelial cell markers and the kit can be operated by a medical institution with a clinical laboratory, are suitable for popularization and popularization, need fewer tissue samples and are suitable for early tumor application.

The invention relates to an esophageal squamous cell carcinoma microenvironmental cell marker molecular model and application thereof. The molecular model mainly comprises a-SMA+ (invasive frontier) fibroblasts, CD163+ (interstitial) macrophages, CD117+ (protogenic layer) mastocytes and CD117+ (invasion frontier) mastocytes. The molecular model can be used to predict the prognosis of patients withesophageal squamous carcinoma and group adjuvant treatment sensitivity groups. A kit mainly includes an anti-CD117 protein antibody, an anti-CD163 protein antibody and an anti-a-SMA protein antibody.According to the invention, the combination of three molecules combined with histopathological features predicts patients' prognosis, which has a higher predictive effect than single index detectionand clearly distinguishes patients with esophageal squamous carcinoma adjuvant treatment sensitivity; an immune tissue chemical hypersensitivity two-step method on which the molecular model is based is a mature and reliable method which can be widely used in primary hospitals; and compared with international TNM staging, the molecular model has a higher predictive effect, and is simpler, easier, more sensitive and more specific.

The invention provides polypeptides specifically binding to CD56 molecules (neural cell adhesion molecules) and an application of the polypeptides. The polypeptides are at least one selected from the group consisting of a No.7 polypeptide and a No.8 polypeptide, and the amino acid sequence of the No.7 polypeptide is shown as a sequence 1 in a sequence table and the amino acid sequence of the No.8 polypeptide is shown as a sequence 2 in the sequence table. The polypeptides provided by the invention can specifically bind to the CD56 molecules, and can be produced by an artificial synthetic method or a genetic engineering method. Compared with antibodies, the polypeptides provided by the invention have the following characteristics: the polypeptides are easy to prepare, and have a small molecular weight, an immunological rejection reaction is not easy to produce and the like; and the polypeptides have small toxic and side effects, and after binding to CD56 positive cells, the polypeptides do not have an obvious killing ability or proliferation inhibition effect. The polypeptides provided by the invention can be used as CD56 positive expression cell markers, and the polypeptides can also be used as substitutes for immunofluorescent CD56 antibodies and the like.